Corcept Therapeutics Inc.
) recently announced that it has formed a partnership with
As per the partnership, Corcept's Korlym will be available to
patients outside the U.S. through a global program, Idis Access
Program. Korlym is approved in the U.S. as a once-daily oral
medication for the treatment of hyperglycemia secondary to
endogenous Cushing's syndrome in adults who have type II diabetes
or glucose intolerance and cannot undergo a surgery.
We note that Korlym was launched by Corcept in the U.S. in Apr
2012. The U.S. Food and Drug Administration (FDA) approved the
drug in Feb 2012.
The program enables patients to obtain access to
investigational or approved drugs before the drugs are
commercially launched in their country. The access is obtained
through a regulatory-compliant and ethical channel on a
We note that Corcept enjoys orphan drug designation for Korlym
from the FDA for the approved indication. The European Commission
also granted orphan drug designation to Korlym for the treatment
of endogenous Cushing's syndrome in Oct 2011.
We note that Korlym is the only approved drug at Corcept.
Hence the successful commercialization of Korlym continues to be
a priority for Corcept. Corcept's partnership with Idis will
allow physicians to prescribe Korlym outside the U.S. as
We remind investors that Corcept also has an ongoing phase III
study on mifepristone, the active ingredient in Korlym, for the
treatment of psychotic depression.
Corcept currently carries a Zacks Rank #3 (Hold). Right now,
WuXi PharmaTech (Cayman) Inc.
) look attractive. All three carry a Zacks Rank #1 (Strong
ACTELION LTD (ALIOF): Get Free Report
CORCEPT THERAPT (CORT): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.